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Abstract
The major complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against
factor VIII (FVIII). The current method for eradicating inhibitors, termed immune tolerance induction (ITI), is costly and
protracted. Clinical protocols that prevent rather than treat inhibitors are not yet established. Liver-directed gene therapy
hopes to achieve long-term correction of the disease while also inducing immune tolerance. We sought to investigate the
use of adeno-associated viral (serotype 8) gene transfer to induce tolerance to human B domain deleted FVIII in hemophilia
A mice. We administered an AAV8 vector with either human B domain deleted FVIII or a codon-optimized transgene, both
under a liver-specific promoter to two strains of hemophilia A mice. Protein therapy or gene therapy was given either alone
or in conjunction with anti-CD20 antibody-mediated B cell depletion. Gene therapy with a low-expressing vector resulted in
sustained near-therapeutic expression. However, supplementary protein therapy revealed that gene transfer had sensitized
mice to hFVIII in a high-responder strain but not in mice of a low-responding strain. This heightened response was
ameliorated when gene therapy was delivered with anti-murine CD20 treatment. Transient B cell depletion prevented
inhibitor formation in protein therapy, but failed to achieve a sustained hypo-responsiveness. Importantly, use of a codon-
optimized hFVIII transgene resulted in sustained therapeutic expression and tolerance without a need for B cell depletion.
Therefore, anti-CD20 may be beneficial in preventing vector-induced immune priming to FVIII, but higher levels of liver-
restricted expression are preferred for tolerance.
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Introduction
Approximately 25% of patients with the X-linked bleeding
disorder hemophilia A (factor VIII, FVIII, deficiency) form
inhibitory antibodies (inhibitors) to FVIII protein during replace-
ment therapy. High-titer inhibitors (.5 BU) render treatment
with FVIII impossible and necessitate the use of ‘‘bypassing’’
agents such as activated factor VII [1]. Inhibitors can be
eradicated through a costly and protracted regimen known as
‘‘immune tolerance induction’’ (ITI). In ITI, patients are
administered repeated high doses of FVIII for a period of up to
1–2 years. Although successful eradication occurs in .50% of
patients, the cost can be upwards of $1,000,000 per patient [1,2].
Thus, strategies to improve ITI or to induce tolerance to FVIII are
highly desirable. One approach is through the use of the biologic
drug rituximab-a monoclonal chimeric antibody directed against
human CD20 originally developed to treat B cell lymphoma.
Rituximab efficiently depletes CD20-expressing B cells via several
mechanisms that include complement, antibody-mediated cellular
cytotoxicity and direct induction of apoptosis [3]. CD20 is
expressed from the early pre-B cell stage to mature B cells and
short-lived plasma cells but not by long-lived plasma cells.
Rituximab has been investigated for use in antibody-mediated
autoimmune diseases such as acquired hemophilia, systemic lupus
erythematosus, rheumatoid arthritis, multiple sclerosis, myasthenia
gravis, and others [4]. Several case reports and one national survey
have revealed that rituximab can improve ITI in hemophilia A
patients, especially in cases where patients have previously failed
traditional ITI [5–7]. Successful reversal of an inhibitor against
factor IX (FIX) that had formed in a non-human primate after
gene therapy was also reported using rituximab combined with
cyclosporine A [8]. However, pre-clinical studies using aCD20 in
hemophilic animals or in gene therapy for hemophilia are very
limited. B cell depletion as a potential means of preventing (rather
than reversing) inhibitor formation has also not been studied.
Interestingly, liver-directed gene therapy with adeno-associated
virus (AAV) can provide both long-term phenotypic correction
and immune tolerance to FIX in hemophilia B animal models [9].
Success in animal models has led to two clinical trials for
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hemophilia B using liver-directed AAV gene therapy [10].
Hemophilia A has been more difficult to treat with AAV gene
therapy due to the increased immunogenicity of FVIII as well as
limitations in the packaging capacity of AAV and in expression of
FVIII. Typically, transient immune suppression, high vector doses,
the use of canine FVIII (which has a higher specific activity in mice
than hFVIII) and mice of C57BL/6 strain background (which is
more promiscuous to hepatic AAV transduction), or a combina-
tion of these methods was needed to achieve long-term correction
in hemophilia A mice [11–13]. Here, we investigate liver-directed
AAV gene therapy in different strains of hemophilia A mice to
induce tolerance to hFVIII either alone or in combination with
transient B cell depletion.
Results
Combination of hepatic gene transfer and transient B cell
depletion
This study sought to identify pathways toward immune
tolerance to hFVIII in gene therapy and to determine the effect
of transient B cell depletion on hFVIII-specific immune responses
(using an anti-murine CD20 comparable to rituximab). Hemo-
philia A mice on either a mixed BL/6-129/sv (BL/6-129/sv-HA)
or a BALB/c (BALB/c-HA) background were divided into two
treatment groups (Fig. 1A). ‘‘AAV8-F8+aCD20’’ mice were given
10 mg/kg of aCD20 one week prior to receiving 1011vg/mouse of
an AAV8 vector expressing B domain-deleted hFVIII under the
liver-specific hAAT promoter (AAV8-F8). Two weeks following
AAV8-hF8 injection (3 weeks following initial aCD20 injection),
mice received another dose of aCD20. Mice in the group ‘‘AAV8-
F8’’ received only the AAV8-hF8 vector (but not aCD20). Ten
weeks following vector administration, all mice were challenged
with weekly IV infusions of 1 IU hFVIII per mouse for 4 weeks
(which reliably results in inhibitor formation in both strains). In
case of BALB/c-HA mice, another 1-month challenge with weekly
hFVIII injections was performed starting 22 weeks after gene
transfer, and blood was collected within 15 min after the fourth
hFVIII injection.
Efficient B cell depletion with aCD20
B cell depletion in lymphoid organs was assessed 1 day and 7
weeks following the second aCD20 injection. CD19+ lymphocytes
were largely absent from all sites investigated one day after the first
or second aCD20 dose (Fig. 1B and data not shown for 1d post
first injection). At 7 weeks after the second aCD20 dose
(concurrent with initial hFVIII challenge), this B cell population
had returned to normal levels in the spleen and lymph nodes and
near normal levels in peripheral blood (Fig. 1B). Absolute T cell
numbers, as measured by total CD3+ cells per 10,000 total cells in
each organ, were not affected by treatment (data not shown).
Thus, mice were deemed to be immune competent at time of
hFVIII challenge.
Lack of CD20+ B cells at the time of gene transfer renders
BL/6-129/sv-HA mice hyporesponsive to hFVIII
BL6-129/sv-HA showed modest correction of clotting times
below that of untreated mice but this correction was minimal
(#1% of normal FVIII activity) regardless of aCD20 treatment
(Fig. 2A). Without further manipulation, this level of correction
was sustained for at least 4 months. However, those mice that were
challenged with supplementary hFVIII therapy lost correction
concurrent with the development of inhibitors (Fig. 2C). ‘‘Con-
trol’’ age-matched mice (no gene transfer) receiving identical
hFVIII challenge had an average Bethesda titer of 154644 BU,
whereas mice receiving AAV8-hF8 had a higher average titer of
336688 ng/mL, suggesting that AAV-hF8 treatment primed the
mice against hFVIII. However, transient B cell depletion with
aCD20 at the time of AAV8-hF8 gene transfer resulted in
subsequent hyporesponsiveness to hFVIII with a significantly
lower Bethesda titer (22611 BU). These titers were 15 times lower
than in mice receiving AAV8-hF8 without aCD20 and 7-fold
lower than mice receiving only protein challenge. These results
were also reflected in total circulating anti-hFVIII IgG1 as
determined by ELISA (Fig. 2B). Mice in the ‘‘aCD20+AAV8-
F8’’ group had a mean IgG1 titer of 16096868 ng/mL, which
was significantly lower than both control and AAV8-hF8 mice
(which had titers of 598861520 ng/mL and 70016867 ng/mL,
respectively).
AAV8-hFVIII gene transfer makes BALB/c-HA mice
hyporesponsive to hFVIII regardless of B cell depletion
The above experiments were repeated in hemophilic mice
carrying the same mutation on a BALB/c background. All BALB/
c-HA mice receiving AAV8-hF8 had ,1% FVIII activity, which
was again sustained in the absence of further manipulation
(Fig. 3A). Coagulation times of mice challenged with hFVIII
increased to or near the uncorrected range. However, 8/9 mice in
the ‘‘AAV8-F8+aCD20’’ group and 5/6 mice in the ‘‘AAV8-F8’’
group had at most low-titer inhibitors (,5 BU), and undetectable
anti-hFVIII IgG1 (Fig. 3B and 3C). This was in contrast to
control mice (no gene transfer or aCD20), which developed
significantly higher anti-hFVIII IgG1 and significantly higher
inhibitor titers (11-fold and 4-fold higher BU than ‘‘AAV-F8’’ and
‘‘AAV8-F8+aCD20’’ mice, respectively) (Fig. 3B and 3C).
Another control group, ‘‘aCD20’’ mice, had received the same
doses of aCD20 (but no gene transfer) followed by hFVIII
challenge (following identical time lines). These mice developed
similar Bethesda titers as the other control mice (Fig. 3B), albeit
anti-FVIII IgG1 titers were somewhat lower (10676297 ng/mL
for ‘‘aCD20’’ vs. 27866693 ng/mL for control; Fig. 3C).
We next wanted to determine if hyporesponsiveness would be
maintained after another round of challenge, and if the
supplementary exogenous hFVIII could correct the aPTT of
vector-treated mice. The lack of humoral immune response was
maintained in all but one mouse in the ‘‘AAV8-F8’’ group as
measured by hFVIII-specific IgG (data not shown). In naı¨ve
BALB/c-HA mice, injection of 1 IU hFVIII resulted in correction
of the aPTT to 4962 sec at a 15-min time point (Fig. 3D). Mice
in ‘‘AAV8-F8’’ and ‘‘AAV8-F8+aCD20’’ groups also showed
correction with average clotting times of 5863 sec and 6064 sec,
respectively. While this level of correction was not quite as good as
for naı¨ve mice, the difference did not reach statistical significance.
No or marginal correction was achieved in control mice that had
formed high-titer inhibitors (Fig. 3D). In summary, we conclude
that treatment of BALB/c-HA mice with AAV8-hFVIII with or
without B cell depletion confers a level of long-term tolerance to
hFVIII that protects from high-titer inhibitors in subsequent
protein therapy, thereby allowing for correction of coagulation.
Induction of CD4+ T cell tolerance to hFVIII
Inhibitor formation is dependent on T help and may be
controlled by Treg. The BALB/c-HA strain was chosen for
analyses of T cell responses to FVIII because this strain responded
better to tolerance induction and, representing a pure strain
background, could be used for adoptive transfer studies. Quan-
titative RT-PCR on in vitro hFVIII-stimulated CD4+ splenocytes
was performed to test for induction of T cell tolerance. Responses
in mice previously treated with AAV8-hFVIII+aCD20, AAV8-
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hFVIII only, or control mice (that had received protein challenge
only) were measured after the last round of challenge with hFVIII
protein had been completed. Bulk splenocytes were stimulated in
vitro with hFVIII and subsequently sorted based on CD4
expression. RNA from CD4+ T cells was used in qRT-PCR to
analyze the transcription of 9 different genes related to T cell
immunity. CD4+ cells from control mice, which had developed
high-titer inhibitors, showed increased transcription of a mix of
Th1, Th2 and suppressive cytokine/marker genes including IL-2,
IL-4, IL-13, IFN-c, FoxP3, CTLA-4, and IL-10, and more
modestly of TGF-b (Fig. 4A). Mice receiving AAV8-hFVIII alone
showed a substantial reduction in their IL-2 and IL-10 responses
and a partial reduction in IL-4 and IL-13 gene expression, while
IFN-c and also Treg markers remained similarly up-regulated as
in controls. The ‘‘AAV8-F8+CD20’’ group showed a broad T cell
unresponsiveness. Only IL-10 and CTLA-4 were marginally
induced in response to FVIII.
The potential role of Treg in tolerance was further investigated
by adoptive transfer of CD4+CD25+ cells harvested from ‘‘AAV8-
F8+aCD20’’ or ‘‘AAV8-F8’’ mice after the first challenge only
modestly suppressed anti-hFVIII formation in recipient mice
(which did not reach statistical significance, Fig. 4B).
hFVIII protein administration during recovery of B cells
fails to achieve lasting tolerance
Next we investigated whether B cell depletion could be
combined with hFVIII protein administration to induce tolerance
to hFVIII. Mice from each strain were given aCD20 as before at
week 0 and 3. Starting at week 7 (i.e. 4 weeks past the last aCD20
dose), when B cells were still recovering, mice were given 4 weekly
IV doses of 1 IU of hFVIII. Mice were bled 2 weeks later to test
for antibody formation. Initially, mice treated with aCD20 were
either non-responsive or hyporesponsive to challenge. Only 1 of 8
BL/6-129/sv-HA mice had detectable anti-FVIII antibodies
(513 ng/mL; 3 BU), whereas 3/7 BALB/c-HA mice had detect-
able (albeit low-titer) inhibitors (Fig. 5A,B). As expected, control
mice (no aCD20 treatment) developed high-titer inhibitors. The
hFVIII treatment protocol was repeated at weeks 14–17 and 21–
24. After the second challenge, only 2 of the BL/6-129/sv-HA
mice remained unresponsive, whereas all other mice developed an
antibody response similar to controls after the first challenge. As
expected, control mice showed further increases in both IgG and
Bethesda titers. By the third challenge, all mice treated with
aCD20 had developed a humoral immune response to hFVIII
similar in magnitude to the controls after two challenges
(Fig. 5A,B). Therefore, transient B cell depletion merely delayed
the antibody response to hFVIII protein.
Higher hepatic expression improves efficacy and
tolerance induction
We also tested an AAV8 vector containing codon-optimized
hFVIII (AAV8-cohFVIII). Identical doses of this vector resulted in
drastic improvements of clotting times in both strains, with
average aPTTs declining from 7868 sec to 3762 sec in the BL/
Figure 1. Depletion of B cells using anti-CD20. A. Treatment schedule. Hemophilia A (HA) mice in ‘‘aCD20’’ groups received a dose of 10 mg/kg
IgG2a aCD20 i.v. on day 0 and day 21. One week following the first aCD20 injection, mice in ‘‘AAV8’’ groups received 1011 vg/mouse of AAV8-hFVIII.
Blood samples were collected at indicated time points. Mice were challenged with intravenous hFVIII (1 IU/mouse, weekly for 4 weeks) at indicated
time points. B. Representative examples of B cell depletion in different lymphoid organs of BALB/c-HA mice 1 day and 7 weeks after the second
injection second aCD20 injection. Numbers in each histogram represent percent CD19+ lymphocytes (as shown by forward and side scatter gating in
left panel) for both untreated control (in black) and aCD20-treated animals (red). Cells were stained with anti-CD19 antibody conjugated to V450
fluorochrome at 1 day post second injection, or to APC-Cy7 for the 7-weeks post-aCD20 time point.
doi:10.1371/journal.pone.0037671.g001
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6-129/sv-HA mice and from 9068 sec to 4362 sec in BALB/c-
HA mice after 4 weeks (Fig. 6A). Clotting times generally rose
over the following 4 weeks but then stabilized. Means of 5364 sec
in BL/6-129/sv-HA and 6166 sec for BALB/c-HA mice were
measure at 18 weeks. Initially, hFVIII activities were 1061% and
861% in BL/6-129/sv-HA and BALB/c-HA mice, respectively,
with a decline to 461% and 261% (Fig. 6B). Following challenge
with hFVIII protein, 3 of 4 mice in the BL/6-129/sv showed no
antibody response to hFVIII with the other having a muted IgG1
titer of 603 ng/mL compared with an average of 598863040 ng/
mL in control animals challenged in the same manner (Fig. 6C).
This animal also had a low Bethesda titer of 1.4 BU (Fig. 6D),
resulting in a longer aPTT (64.9 sec) compared to the other mice
at 18 weeks post vector injection. In BALB/c-HA mice, no anti-
hFVIII antibodies were detected in 2/4 mice, while the other 2
mice had very low but detectable antibody titers after challenge
(830 and 443 ng IgG1 anti-hFVIII/mL, corresponding to 1.4 and
0.6 BU, Fig. 6C,D). Average anti-FVIII titers of the control
group were 27856693 ng/mL or 1765 BU. In summary, a
highly significant 9–10-fold reduction in antibody response to
hFVIII protein was achieved with the cohFVIII construct
including a complete lack of response to hFVIII protein in 5/8
mice.
Adoptive transfer of CD4+CD25+ Treg was also performed as
above with tolerant AAV8-coFVIII-treated BALB/c-HA mice
serving as donors. Recipient mice showed a significantly lower
antibody response to FVIII compared to mice receiving
CD4+CD25+ T cells from naı¨ve mice (Fig. 4B). Therefore, the
use of cohFVIII induced a more potent Treg response than wild-
type cDNA.
Discussion
Given the recent success with hepatic AAV8 gene transfer in
patients with severe hemophilia B, a similar gene therapy for
hemophilia A represents a logical progression [14]. However,
therapeutic AAV-FVIII gene transfer in animal models has
required substantially higher vector doses and the risk of inhibitor
formation is generally greater for hemophilia A. We previously
demonstrated tolerance induction to FIX by AAV gene transfer to
the liver of hemophilic animals, which was particularly effective
when using AAV8-a serotype that is highly effective in transducing
murine hepatocytes [9,15]. However, a minimal level of transgene
expression was required.
Gene transfer may tolerize or sensitize mice depending
on genetic background
If gene transfer only accomplished expression at the lower end
of the therapeutic range, e.g. ,5% of normal, this would
occasionally necessitate supplementary clotting factor administra-
tion. Hence, it is imperative that tolerance is maintained under
these circumstances. Previously, sustained correction of murine
hemophilia A with AAV vectors has been shown using either
cFVIII or murine FVIII, but neither study tested the effect of
FVIII challenge after gene therapy [16,17]. Others have combined
gene transfer with immune suppression to avoid inhibitor
formation [11–13,16]. Our study shows that lack of inhibitor
formation against FVIII after hepatic AAV gene transfer does not
necessarily constitute humoral immune tolerance as mice in both
strains treated with a low-expressing vector maintained correction
in absence of but not after challenge with hFVIII (Figs. 2A and
3A). In fact, in the BL/6-129/sv-HA strain, mice were predisposed
to heightened inhibitor formation in subsequent treatment with
hFVIII protein, while gene transfer had the desired tolerogenic
effect in BALB/c-HA mice. Clearly, high levels of hepatic
expression promote tolerance regardless of the strain background
(Fig. 6), which is consistent with our earlier findings on factor IX
[9]. However, within the range of sub-optimal expression, two
Figure 2. Depletion of B cells combined with gene therapy in
BL/6-129/sv-HA mice. A. Activated partial thromboplastin time
(aPTT) of mice receiving 1011vg/mouse of AAV8-hFVIII either alone
(‘‘AAV8-F8’’) or in combination with aCD20 therapy (‘‘AAV8-F8+CD20’’).
‘‘FVIII challenge’’ indicates a period of weekly HFVIII injections (see Fig.
1A). ‘‘AAV8-unchallenged’’ group is mice that received vector but were
not challenged with hFVIII protein. Range of aPTT for untreated mice
and coagulation time for HA mouse plasma corrected to 1% HFVIII
activity are also shown. Data are average values 6SD for n = 5 per
experimental group. Two weeks after completion of the FVIII challenge,
antibody formation against FVIII was measured: B. Total FVIII-specific
IgG1 levels as determined by ELISA. C. Inhibitory antibody titers as
measured by Bethesda assay (in BU). Values in panels B and C are
shown for individual animals and as averages 6SD. Statistically
significant differences between groups are indicated.
doi:10.1371/journal.pone.0037671.g002
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possibilities may explain the differing responses between the two
strains. Somewhat higher expression in BALB/c-HA mice may
have been partially effective in tolerance induction, while
expression in the BL/6-129/sv-HA strain may have been just
below this threshold and thus sensitized the mice. Alternatively,
similarly low levels of expression may sensitize animals with higher
immune responsiveness to F.VIII, while having a more tolerogenic
effect in a strain with lower responsiveness.
Consistent with data by others, BALB/c-HA mice had lower
inhibitor responses against hFVIII, and T helper responses
differed between strains [18]. BL/6-129/sv-HA mice, after 4
weeks of hFVIII protein therapy, had 10-fold higher inhibitor
titers compared to BALB/c-HA. However, IgG formation against
hFVIII was only 2-fold higher (compare Figs. 2 and 3). In
contrast to BL/6-129/sv-HA, BALB/c-HA mice only showed a
good correlation between BU and IgG titers after a longer course
of hFVIII administration (data not shown). Previously, we
documented that CD4+ T cell responses against hFVIII in BL/
6-129/sv-HA mice were strongly biased to Th2, characterized by
IL-4 and IL-6 production while lacking expression of suppressive/
regulatory cytokines [19]. BALB/c-HA mice, however, have a
more mixed response, which includes expression of Th1, Th2, and
suppressive molecules (Fig. 4A). This difference in the T helper
response likely explains differences in inhibitor responses and in
ability to induce tolerance in the 2 strains. Despite evidence for
Th1 activation as part of the CD4+ T cell response in BALB/c-
HA, we found that mice of both strains formed IgG2a against
hFVIII only rarely and inconsistently (data not shown), suggesting
that antibody formation is primarily driven by the Th2 compo-
nent, thus consistently resulting in high-titer IgG1.
Tolerance induction with codon-optimized hFVIII
It is encouraging that a more effective codon-optimized hFVIII
expression cassette induced humoral tolerance, resulting in
sustained correction of coagulation after challenge with hFVIII
protein, independent of the strain background. This is significant
in light of the fact that hFVIII has been notoriously difficult to
express in mice at levels high enough for phenotypic correction.
Often, alternative species FVIII have been used such as canine
FVIII or porcine FVIII because of either higher expression or
superior secretion [13,17,20,21]. Here, we were able to achieve
tolerance to hFVIII and long-term phenotypic correction with a
single AAV vector expressing codon-optimized hFVIII in the
absence of immune suppression. Codon optimization is a process
whereby the cDNA to be expressed is analyzed and altered to
improve expression based on a variety of factors including but not
limited to: usage of species-specific codons, increased GC content,
removal of cryptic slice sites, and stabilizing RNA structure [22].
This process has been used in the context of gene therapy to
improve expression of several transgenes from different vectors
[23–28]. Only one study used this approach for hFVIII expression.
Investigators observed up to a 44-fold increase in FVIII expression
following delivery of a codon-optimized hFVIII via lentivirus to
neonatal hemophilia A mice [28]. However, the immunological
Figure 3. B Cell depletion combined with gene therapy in BALB/c-HA mice. A. Activated partial thromboplastin time (aPTT) of mice
receiving 1011vg/mouse of AAV8-hFVIII either alone (‘‘AAV8-F8’’) or in combination with aCD20 therapy (‘‘AAV8-F8+CD20’’). ‘‘FVIII challenge’’ with
weekly hFVIII protein is indicated (see also Fig. 1A). ‘‘AAV8-unchallenged’’ mice received vector but no hFVIII protein. ‘‘aCD20’’ mice received B cell
depletion and hFVIII challenge in the absence of gene transfer. Range of aPTT for untreated mice and coagulation time for HA mouse plasma
corrected to 1% HFVIIII activity are also shown. Data are average values6SD for n = 7–9 mice per experimental group. Two weeks after completion of
the FVIII challenge, antibody formation against HFVIIII was measured: B. Total FVIII-specific IgG1 levels. C. Inhibitor titers (in BU). Values in panels B
and C are shown for individual animals and as averages 6SD. Statistically significant differences between groups are indicated. D. Starting in week
22, mice were given a second round of hFVIII protein challenge (see Fig. 1A). Five min after the last HFVIIII injection, mice were bled via tail vein, and
collected plasma assayed by aPTT (n = 3–4 per experimental group). ‘‘Naı¨ve’’ mice were also treated with hFVIII and bled 5 min later, but had no prior
exposure to hFVIII. ‘‘FVIII-only’’ mice were mice that had been challenged previously with hFVIII (without aCD20 treatment or gene therapy) and thus
had developed inhibitors. ‘‘aCD20+FVIII’’ mice had initially received aCD20 but no gene therapy and developed inhibitors in subsequent protein
therapy (labeled as ‘‘aCD20’’ group in panels A–C). NS: not significant.
doi:10.1371/journal.pone.0037671.g003
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consequences of increased expression in the context of a mature
immune system were not investigated. Here, we demonstrate that
a cohFVIII construct improves not only efficacy but also tolerance
induction in adult hemophilia A mice of two different strains. In
adult animals, Treg induction is a critical component of tolerance
induction by hepatic gene transfer. Our adoptive transfer
experiments showed that use of cohFVIII facilitated Treg
induction, thereby conferring better suppression of antibody
formation against hFVIII.
Utility of transient B cell depletion for tolerance to hFVIII
Rituximab has been used to treat patients with inhibitors with
varying degrees of success [5–7]. In acquired hemophilia, a rare
form of the disease where inhibitors appear in a hemostatically
normal individual, treatment with rituximab alone can eradicate
inhibitors [29]. This response is long-lasting and has been
observed to last up to 5.5 years [29]. In contrast, rituximab use
in X-linked hemophilia A is usually concurrent with traditional
ITI. In this setting, data is limited largely to case reports and well-
controlled studies are lacking. However, a consecutive national
cohort analyzed in the UK investigating the use of rituximab as an
adjunct to traditional ITI suggests a modest benefit of B cell
depletion for eradicating inhibitors in patients who have previously
failed ITI [6]. Still, a number of these individuals (6/10) relapsed
and required additional immune therapy [6]. Our data presented
here also reveal limitations for the use of aCD20. While B cell
depletion effectively prevented anti-hFVIII formation in protein
therapy, such a protocol failed to induce lasting hyporesponsive-
ness, suggesting that protein administration fails to tolerize the
newly emerging B cells. This conclusion is supported by a recent
clinical study where immune responses to neoantigens following
Rituximab treatment were muted during B cell depletion but
returned to near normal once the effects of the drug waned [30].
Furthermore, our experiments using B cell depleting aCD20 in
conjunction with gene therapy suggest its usefulness when there is
concern of low-efficacy gene therapy priming the immune system
Figure 4. T cell responses in BALB/c-HA mice. A. Following the
final tail vein bleed (Fig. 3D), mice were sacrificed and spleens collected.
Splenocyte cultures for individual mice (n = 4 per group) were
stimulated in vitro with 10 mg/mL of hFVIII for 48 h. Subsequently,
CD3+CD4+ T cells were purified by flow cytometry and analyzed by
quantitative RT-PCR for expression of several immune-regulatory genes.
Shown are data for indicated groups (averages 6SD; ‘‘fold increase’’ is
change in RNA transcripts of hFVIIII- vs. mock-stimulated). The dotted
horizontal line indicates the minimally required increase of 2.5-fold for a
statistically significant difference. B. Evidence for Treg induction in mice
that had received gene transfer or a combination of aCD20 and gene
transfer. Following one round of hFVIII challenge, CD4+CD25+
splenocytes were purified from each treatment group via magnetic
sorting, and 106 cells/mouse were adoptively transferred to naı¨ve BALB/
c-HA recipients via tail vein injection. Control cells were from
unchallenged naı¨ve mice of the same strain. Twenty-four hours later,
all recipient mice (n = 3 per group) were challenged with 1 IU hFVIII in
adjuvant. Anti-FVIII IgG titers were measured 1 month later by ELISA.
Data are averages 6SD.
doi:10.1371/journal.pone.0037671.g004
Figure 5. Anti-CD20 treatment to prevent antibody formation
in hFVIII protein replacement therapy. BL/6-129/sv-HA and BALB/
c-HA mice were treated with aCD20 antibody as outlined in Fig. 1A
(indicated with large arrows) followed by 4 weeks of hFVIII challenge
(indicated by small arrows) beginning at 4 weeks after the second
aCD20 administration. Mice were treated with hFVIII twice more
following the same schedule. Antibody formation against HFVIIII was
measured by Bethesda assay (A) and anti-hFVIII IgG1 ELISA (B) two
weeks after each 4-week challenge. Control mice did not receive aCD20.
Gray triangles represent B cell recovery. Data are averages 6SD for
n = 3–5/group.
doi:10.1371/journal.pone.0037671.g005
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to hFVIII. This indicates a role of B cells in the generation of a
primary immune response to hFVIII. This was not due to long-
term effects of aCD20 as transient B cell depletion did not reduce
the ability of control animals to form antibodies once B cell
frequencies had recovered. To further confirm this point, we
administered an adenoviral vector expressing b-galactosidase 7
weeks after the second dose of aCD20. The mice formed
neutralizing antibodies against the virus and antibodies against
b-galactosidase at titers indistinguishable from control mice (data
not shown).
Low levels of hepatic expression resulted only in a partial
reduction of the T cell response to FVIII in BALB/c-HA mice,
despite the protective effect against inhibitor formation. The
reduction of the Th2 response, in conjunction with preserving
Treg responses, was likely instrumental in achieving this effect.
Nonetheless, gene transfer combined with aCD20 treatment
induced a broad T cell unresponsiveness. Interestingly, up-
regulation of Treg markers was also abrogated. This was
somewhat reflected in adoptive transfer experiments, where
CD4+CD25+ cells from AAV8-F8-only treated mice showed a
trend for greater suppression compared to cells from ‘‘AAV8-
F8+aCD20’’ mice, although this did not reach significance. In
contrast, high expression from the codon-optimized construct
increased the suppressive response in the presence of B cells, which
raises the question of how the combination of these two
approaches may shape the response. B cells play a dual role in
the immune response as antigen presenting cells and as producers
of antibodies. Zhang et al. demonstrated in mice that treatment
with aCD20 similarly prevented a secondary immune response to
protein challenge in hFVIII-primed hemophilia A mice [31].
Interestingly, these authors found that IgG1 instead of IgG2a
aCD20 spared marginal zone B cells and caused accumulation of
Treg after further exposure to hFVIII. Furthermore, a recent
study by Xiang et. al investigating the effect of B cell depletion on
T cell function and phenotype [32]. In their model, Treg were
initially reduced following B cell depletion but actually increased
when B cells have recovered, and there was also evidence for
emergence of suppressive B cells. Thus, a more differential method
for B cell targeting may further improve tolerance induction by
this approach.
In conclusion, transient B cell depletion and even more so use of
a codon-optimized FVIII sequence in hepatic gene transfer
represent promising strategies to avoid inhibitor formation and
promote tolerance in gene therapy for hemophilia A. Therefore,
adding a different and superior method for tolerance induction
such as hepatic gene transfer may improve the usefulness of
rituximab for elimination of inhibitors in congenital hemophilia.
Going forward, it will be critical to determine whether transient B
cell depletion combined with use of a codon-optimized expression
cassette synergize in inducing tolerance to hFVIII, and what the
effect on T effector and Treg responses will be. In addition, anti-
CD20 treatment may facilitate both tolerance to the transgene
product and re-administration of vector by preventing neutralizing
antibodies against the vector capsid.
Figure 6. Codon-optimized hFVIII to induce tolerance and correction. BALB/c-HA and BL/6-129/sv-HA mice were injected with 1011vg/
mouse of an AAV8 vector expressing codon-optimized hFVIII. A. Coagulation times (aPTT in sec) and B. HFVIIII activity were measured as a function
of time after vector administration. Data are averages 6SD for n = 4/group. Mice were challenged (starting at week 10 after gene transfer) with hFVIII
at the same dose and schedule as in previous experiments. Anti-hFVIII formation was measured C. as HFVIIII-specific IgG1 titers, and D. by Bethesda
assay. Values in panels C and D are shown for individual animals and as averages 6 SD and plotted on the same scale as in Fig. 2 to compare
magnitude of responses.
doi:10.1371/journal.pone.0037671.g006
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Methods
Ethics statement
This research involved hemophilic mice. These studies
(Approval ID # 01321, ‘‘Immunology of factor IX gene transfer
to liver’’, and Approval ID # 03971, ‘‘Pathways towards immune
tolerance to coagulation factors’’) were approved by the respective
Institutional Animal Care and Use Committees (IACUC) at the
University of Florida and the NIDCR (NIH). All procedures were
done in accordance with the principles of the National Research
Council’s Guide for the Care and Use of Laboratory Animals.
Studies were conducted in male mice housed at 22–24uC in a
12 hours light/dark cycle. Mice had free access to water and food
unless indicated otherwise.
Mouse strains
All animals used were 6–10-week old male hemophilia A mice
with a deletion in Exon 16 of the mFVIII gene on either BALB/c
or a mixed C57BL/6-129/sv background, kindly provided by Drs.
Lillicrap and Kazazian [33].
B cell depletion and flow cytometry
Mice were depleted of B cells using 10 mg/kg of anti-murine
CD20 IgG2a antibody (clone 18B12, kindly provided by Biogen
Idec) [34]. Mice were given two IV doses 21 days apart. To assess
B cell depletion, lymphoid tissues were collected either 1 day or 7
weeks after the second dose. Peripheral blood was collected in
heparinized microcapillary tubes via retro-orbital plexus, centri-
fuged to remove plasma, and remaining cells suspended in PBS for
flow cytometry. Single cell suspensions of splenocytes and
peripheral lymph node cells were stained with fluorescently
labeled antibodies for the B cell marker CD19 as well as CD3
or CD4 to detect T cells. Lymphocyte gating was determined by
forward-scatter and side-scatter following back gating for the area
containing CD19+ cells. A BD LSRII flow cytometer (BD
Biosciences, Frederick, MD, USA) and FCS Express 4 software
(Denovo Software, Los Angeles, CA, USA) were used for analysis.
Vectors and mouse procedures
Mice were given a tail vein injection of 1011vg/mouse of AAV8
containing either wild-type or codon-optimized B domain-deleted
human hFVIII (BDD-hFVIII) under a liver-specific promoter.
This construct was assembled by replacing the transthyretin
promoter of the vector published by Lu et al. [12] with the ApoE/
hAAT enhancer/promoter [9]. The codon-optimized cDNA was
synthesized by GeneArt (Regensburg, Germany). Tail bleeds as
described previously [35]. For hFVIII challenge, mice were
administered 1 IU BBD-hFVIII (Xyntha, Pfizer, New York, NY)
once a week for 4 weeks beginning at week 10 after vector
administration. Collected blood was used to determine activated
partial thromboplastin time (aPTT), while antibody responses
were measured via ELISA for total anti-hFVIII IgG and by
Bethesda assay as described [35]. For hFVIII % activity, a
standard curve was developed using the same BDD-hFVIII used
for challenge diluted in naı¨ve hemophilia A mouse plasma.
T cell assays and adoptive transfer
Splenocytes were isolated from mice in each group and cultured
in RPMI 1640 media containing 5 mM b-mercaptoethanol,
100 mM insulin/transferrin/selenium, glutamine and pencillin/
streptomycin either with or without 5 mg/mL of hFVIII for 48 h
at 37uC and 5% CO2. Cells were then removed and sorted for
CD3+CD4+ cells on an ARIA cell sorter (BD Biosciences, San
Jose, CA, USA). RNA was immediately extracted from these cells
using the Qiagen RNeasy isolation kit (Valencia, CA, USA) and
used for quantitative RT-PCR with SA Biosciences arrays. Splenic
CD4+CD25+ cells were purified with the magnetic isolation kit
from Miltenyi Biotec (Bergisch Gladbach, Germany), which
achieved ,85% purity. These cells were then pooled and
adoptively transferred to naı¨ve BALB/c-HA mice at 106 cells/
mouse via tail vein injection. Recipient mice were challenged
24 hours later via subcutaneous injection of 1 IU hFVIII in Sigma
Adjuvant System (St. Louis, MO, USA).
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